|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual Report to the Nation on the Status of Cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang ZY: Hepatocellular carcinoma--cause,
treatment and metastasis. World J Gastroenterol. 7:445–454. 2001.
View Article : Google Scholar
|
|
4
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Craig AJ, von Felden J, Garcia-Lezana T,
Sarcognato S and Villanueva A: Tumour evolution in hepatocellular
carcinoma. Nat Rev Gastroenterol Hepatol. 17:139–152. 2020.
View Article : Google Scholar
|
|
6
|
Perk J, Iavarone A and Benezra R: Id
family of helix-loop-helix proteins in cancer. Nat Rev Cancer.
5:603–614. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sachdeva R, Wu M, Smiljanic S, Kaskun O,
Ghannad-Zadeh K, Celebre A, Isaev K, Morrissy AS, Guan J, Tong J,
et al: ID1 is critical for tumorigenesis and regulates
chemoresistance in glioblastoma. Cancer Res. 79:4057–4071. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang YH, Hu J, Chen F, Lecomte N, Basnet
H, David CJ, Witkin MD, Allen PJ, Leach SD, Hollmann TJ, et al: ID1
mediates escape from TGFβ tumor suppression in pancreatic cancer.
Cancer Discov. 10:142–157. 2020. View Article : Google Scholar
|
|
9
|
Gumireddy K, Li A, Kossenkov AV, Cai KQ,
Liu Q, Yan J, Xu H, Showe L, Zhang L and Huang Q: ID1 promotes
breast cancer metastasis by S100A9 regulation. Mol Cancer Res.
12:1334–1343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Román M, López I, Guruceaga E, Baraibar I,
Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, et
al: Inhibitor of differentiation-1 sustains mutant KRAS-driven
progression, maintenance, and metastasis of lung adenocarcinoma via
regulation of a FOSL1 network. Cancer Res. 79:625–638. 2019.
View Article : Google Scholar
|
|
11
|
Fong S, Debs RJ and Desprez PY: Id genes
and proteins as promising targets in cancer therapy. Trends Mol
Med. 10:387–392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ao J, Meng J, Zhu L, Nie H, Yang C, Li J,
Gu J, Lin Q, Long W, Dong X, et al: Activation of androgen receptor
induces ID1 and promotes hepatocellular carcinoma cell migration
and invasion. Mol Oncol. 6:507–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin X, Tang B, Li JH, Wang Y, Zhang L, Xie
XY, Zhang BH, Qiu SJ, Wu WZ and Ren ZG: ID1 promotes hepatocellular
carcinoma proliferation and confers chemoresistance to oxaliplatin
by activating pentose phosphate pathway. J Exp Clin Cancer Res.
36:1662017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niu LL, Cheng CL, Li MY, Yang SL, Hu BG,
Chong CCN, Chan SL, Ren J, Chen GG and Lai PBS: ID1-induced p16/IL6
axis activation contributes to the resistant of hepatocellular
carcinoma cells to sorafenib. Cell Death Dis. 9:8522018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marumoto T, Zhang D and Saya H: Aurora-A -
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang A, Gao K, Chu L, Zhang R, Yang J and
Zheng J: Aurora kinases: Novel therapy targets in cancers.
Oncotarget. 8:23937–23954. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeng YM, Peng SY, Lin CY and Hsu HC:
Overexpression and amplification of Aurora-A in hepatocellular
carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tayyar Y, Jubair L, Fallaha S and McMillan
NAJ: Critical risk-benefit assessment of the novel anti-cancer
aurora a kinase inhibitor alisertib (MLN8237): A comprehensive
review of the clinical data. Crit Rev Oncol Hematol. 119:59–65.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beltran H, Oromendia C, Danila DC,
Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong
AJ, Stein M, Pinski J, et al: A phase II trial of the Aurora Kinase
A inhibitor Alisertib for patients with castration-resistant and
neuroendocrine prostate cancer: Efficacy and biomarkers. Clin
Cancer Res. 25:43–51. 2019. View Article : Google Scholar
|
|
20
|
Hasskarl J, Duensing S, Manuel E and
Münger K: The helix-loop-helix protein ID1 localizes to centrosomes
and rapidly induces abnormal centrosome numbers. Oncogene.
23:1930–1938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cowley DO, Rivera-Pérez JA, Schliekelman
M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED, Magnuson T and Van
Dyke T: Aurora-A kinase is essential for bipolar spindle formation
and early development. Mol Cell Biol. 29:1059–1071. 2009.
View Article : Google Scholar :
|
|
22
|
Nikonova AS, Astsaturov I, Serebriiskii
IG, Dunbrack RL Jr and Golemis EA: Aurora A kinase (AURKA) in
normal and pathological cell division. Cell Mol Life Sci.
70:661–687. 2013. View Article : Google Scholar
|
|
23
|
Meraldi P, Honda R and Nigg EA: Aurora-A
overexpression reveals tetraploidization as a major route to
centrosome amplifi-cation in p53-/- cells. EMBO J. 21:483–492.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Man C, Rosa J, Yip YL, Cheung AL, Kwong
YL, Doxsey SJ and Tsao SW: Id1 overexpression induces
tetraploidization and multiple abnormal mitotic phenotypes by
modulating aurora A. Mol Biol Cell. 19:2389–2401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 practice
guidance by the american association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Llovet JM, Fuster J and Bruix J;
Barcelona-Clínic Liver Cancer Group: The Barcelona approach:
Diagnosis, staging, and treatment of hepatocellular carcinoma.
Liver Transpl. 10(Suppl 1): S115–S120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL,
Liu YK and Tang ZY: Stepwise metastatic human hepatocellular
carcinoma cell model system with multiple metastatic potentials
established through consecutive in vivo selection and studies on
metastatic characteristics. J Cancer Res Clin Oncol. 130:460–468.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jawhar NM: Tissue Microarray: A rapidly
evolving diagnostic and research tool. Ann Saudi Med. 29:123–127.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Detre S, Saclani Jotti G and Dowsett M: A
'quickscore' method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Wen F and Li Q: FOLFOX4 or
sorafenib as the first-line treatments for advanced hepatocellular
carcinoma: A cost-effectiveness analysis. Dig Liver Dis.
48:1492–1497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multicenter, open-label study of oxaliplatin plus
fluoro-uracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slevin M, Kumar S and Gaffney J:
Angiogenic oligosaccharides of hyaluronan induce multiple signaling
pathways affecting vascular endothelial cell mitogenic and wound
healing responses. J Biol Chem. 277:41046–41059. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Li H, Li CW, Li X, Ding Q, Guo L, Liu S,
Liu C, Lai CC, Hsu JM, Dong Q, et al: MET inhibitors promote liver
tumor evasion of the immune response by stabilizing PDL1.
Gastroenterology. 156(2019): 1849–1861e13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guichard C, Amaddeo G, Imbeaud S, Ladeiro
Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, et al: Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lamb JR, Zhang C, Xie T, Wang K, Zhang B,
Hao K, Chudin E, Fraser HB, Millstein J, Ferguson M, et al:
Predictive genes in adjacent normal tissue are preferentially
altered by sCNV during tumorigenesis in liver cancer and may rate
limiting. PLoS One. 6:e200902011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taguchi S, Honda K, Sugiura K, Yamaguchi
A, Furukawa K and Urano T: Degradation of human Aurora-A protein
kinase is mediated by hCdh1. FEBS Lett. 519:59–65. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Walter AO, Seghezzi W, Korver W, Sheung J
and Lees E: The mitotic serine/threonine kinase Aurora2/AIK is
regulated by phosphorylation and degradation. Oncogene.
19:4906–4916. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li B, Xu WW, Guan XY, Qin YR, Law S, Lee
NPY, Chan KT, Tam PY, Li YY, Chan KW, et al: Competitive binding
between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and
thymidylate synthase expression to promote esophageal cancer
chemoresistance. Clin Cancer Res. 22:1243–1255. 2016. View Article : Google Scholar
|
|
40
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dauch D, Rudalska R, Cossa G, Nault JC,
Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L,
et al: A MYC-aurora kinase A protein complex represents an
actionable drug target in p53-altered liver cancer. Nat Med.
22:744–753. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Otto T, Horn S, Brockmann M, Eilers U,
Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R,
Christiansen H, et al: Stabilization of N-Myc is a critical
function of Aurora A in human neuroblastoma. Cancer Cell. 15:67–78.
2009. View Article : Google Scholar
|
|
43
|
Chuma M, Terashita K and Sakamoto N: New
molecularly targeted therapies against advanced hepatocellular
carcinoma: From molecular pathogenesis to clinical trials and
future directions. Hepatol Res. 45:E1–E11. 2015. View Article : Google Scholar
|
|
44
|
Kononen J, Bubendorf L, Kallioniemi A,
Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G
and Kallioniemi OP: Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Alkushi A: Validation of tissue microarray
biomarker expression of breast carcinomas in Saudi women. Hematol
Oncol Stem Cell Ther. 2:394–398. 2009. View Article : Google Scholar
|
|
46
|
Graham AD, Faratian D, Rae F and Thomas
JS: Tissue microarray technology in the routine assessment of HER-2
status in invasive breast cancer: A prospective study of the use of
immunohistochemistry and fluorescence in situ hybridization.
Histopathology. 52:847–855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Drev P, Grazio SF and Bracko M: Tissue
microarrays for routine diagnostic assessment of HER2 status in
breast carcinoma. Appl Immunohistochem Mol Morphol. 16:179–184.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cho Y, Cho EJ, Lee J-H, Yu SJ, Kim YJ, Kim
CY and Yoon JH: Fucoidan-induced ID-1 suppression inhibits the in
vitro and in vivo invasion of hepatocellular carcinoma cells.
Biomed Pharmacother. 83:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yan M, Wang C, He B, Yang M, Tong M, Long
Z, Liu B, Peng F, Xu L, Zhang Y, et al: Aurora-A Kinase: A potent
oncogene and target for cancer therapy. Med Res Rev. 36:1036–1079.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cammareri P, Scopelliti A, Todaro M,
Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A,
Stassi G, et al: Aurora-A is essential for the tumorigenic capacity
and chemoresistance of colorectal cancer stem cells. Cancer
Research. 70:4655–4665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu
L, Zhao Y, Huang XF, Wang XR, Zhu XF, et al: Inhibition of Aurora-A
suppresses epithelial-mesenchymal transition and invasion by
downregulating MAPK in nasopharyngeal carcinoma cells.
Carcinogenesis. 29:1930–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zheng F, Yue C, Li G, He B, Cheng W, Wang
X, Yan M, Long Z, Qiu W, Yuan Z, et al: Nuclear AURKA acquires
kinase-independent transactivating function to enhance breast
cancer stem cell phenotype. Nat Commun. 7:101802016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hasskarl J, Mern DS and Münger K:
Interference of the dominant negative helix-loop-helix protein ID1
with the proteasomal subunit S5A causes centrosomal abnormalities.
Oncogene. 27:1657–1664. 2008. View Article : Google Scholar
|
|
55
|
Geng F, Wenzel S and Tansey WP: Ubiquitin
and proteasomes in transcription. Annu Rev Biochem. 81:177–201.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Peck-Radosavljevic M: Drug therapy for
advanced-stage liver cancer. Liver Cancer. 3:125–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
